The calcium concentration of peritoneal dialysis solution modifies levels of key mediators of peritoneal fibrosis.

BACKGROUND: To explore the effects of different calcium concentrations of peritoneal dialysis solution (PDS) on continuous ambulatory peritoneal dialysis (CAPD) and expression of vimentin (VIM), fibroblast-specific protein (FSP1), and E-cadherin. MATERIALS AND METHODS: This was a pilot study (#ChiCTR1900021387) conducted from January 2017 to December 2019 at the Hospital. The patients were randomized to undergo CAPD using PDS with a calcium concentration of 1.25 mmol/L (low concentration group) or 1.75 mmol/L (high concentration group). Changes in biochemistry before dialysis and at 6 and 12 months were analyzed. RESULTS: There were 50 and 52 participants in the low and high calcium groups. The blood biochemical indexes were all different between the two groups (all Ptime  < .05, Pgroup  < .05, Pinteraction  < .05), but they remained within their normal ranges. VIM and FSP1 increased over 12 months (Ptime  < .05); VIM and FSP1 levels in the high concentration group were higher than in the low concentration group (Pgroup  < .05, Pinteraction  < .05), while E-cadherin showed the inverse association (Ptime  < .001, Pgroup  < .001, Pinteraction  < .001). There was no difference in complications (P = .973). CONCLUSION: The calcium concentration in PDS might be an important factor affecting the progression of peritoneal fibrosis.